RKDA
Arcadia Biosciences, Inc.
There isn't enough reported data to score RKDA yet.
RKDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
RKDA's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
RKDA PE Valuation
RKDA has no meaningful PE right now: it lost money over the past year.
RKDA Forward outlook
There aren't enough analyst estimates for RKDA to show an outlook.
RKDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.88 | -$1.15 |
| Q2 2026 | -$4.55 | +$0.98 |
| Q1 2026 | -$5.72 | -$4.23 |
| Q4 2025 | -$1.71 | +$3.46 |
| Q3 2022 | -$38.00 | -246% |
| Q2 2022 | -$37.20 | -720% |
| Q1 2022 | -$40.00 | -$14.00 |
| Q4 2021 | -$27.60 | -$8.80 |
RKDA is still losing money, but far less than before: $4.88 per share over the past year, against $181.20 at its worst in late 2019.
RKDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6M | +24% |
| Q2 2026 | $1.4M | -0.8% |
| Q1 2026 | $1.1M | -8.3% |
| Q4 2025 | $901K | -26% |
| Q3 2025 | $1.3M | -15% |
| Q2 2025 | $1.5M | +11% |
| Q1 2025 | $1.2M | -4.4% |
| Q4 2024 | $1.2M | +3.9% |
RKDA's revenue is recovering but still below its 2020 peak: $2M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -52% | +37 points |
| Q2 2026 | -34% | +0.1 points |
| Q1 2026 | -71% | -115 points |
| Q4 2025 | -153% | +35 points |
| Q3 2025 | -88% | +26 points |
| Q2 2025 | -34% | -186 points |
| Q1 2025 | 44% | +288 points |
| Q4 2024 | -187% | +100 points |
RKDA's operating margin was −52% last quarter, up 37 points from the same quarter a year ago.
RKDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.3M | -$1M |
| Q2 2026 | -$319K | +$1.7M |
| Q1 2026 | -$1.1M | +$489K |
| Q4 2025 | -$861K | +$1.3M |
| Q3 2025 | -$257K | +$1.5M |
| Q2 2025 | -$2M | +$426K |
| Q1 2025 | -$1.6M | +$1.6M |
| Q4 2024 | -$2.2M | +$1.9M |
RKDA has burned cash in almost every quarter: −$4M over the past year, against −$6M the year before.
RKDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +103% | +3.1M shares |
| 1 year | +344% | +4.7M shares |
| 3 years | +346% | +4.7M shares |
| 5 years | +1174% | +5.6M shares |
RKDA has 6M diluted shares, up 344% from a year ago.
RKDA Net Leverage
RKDA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RKDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.4 | Oversold |
| Stochastic | 10.8 | Oversold |
RKDA's weekly RSI is 27 (oversold) and its Stochastic is 11 (oversold).
RKDA PE vs Basic Materials Sector
| Metric | RKDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 19x | — |
RKDA has no meaningful PE right now: it lost money over the past year.
RKDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.22 | 0% above |
| 20 week MA | $0.44 | 50% below |
| 50 week MA | $1.24 | 82% below |
| 100 week MA | $2.70 | 92% below |
| 200 week MA | $3.45 | 94% below |
RKDA is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
RKDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $245.6 | $103.2 | -58% |
| 2021 | $103.2 | $42.4 | -59% |
| 2022 | $42.4 | $11.3 | -73% |
| 2023 | $11.3 | $3.13 | -72% |
| 2024 | $3.13 | $6.11 | +95% |
| 2025 | $6.11 | $2.60 | -57% |
| 2026 YTD | $2.60 | $0.22 | -92% |
RKDA has finished lower in five of the last six years. It's down 92% so far in 2026.